Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: Optimized MS parameters for PMX53 and PMX205.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques:

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: HPLC-MS/MS of PMX53 and PMX205: Product ion MS/MS scan spectra and relative intensities of fragment ions following positive (+2) electrospray ionization of PMX53 (m/z 448.6) ( A ) and PMX205 (m/z 420.2) ( B ). Developed MS method under multiple reaction monitoring mode of mass spectrometer combined with liquid chromatography gradient and flow rate conditions ( C ) for fragment ions resulted HPLC-MS/MS chromatograms of analytes as represented by overlayed chromatograms of complement C5a receptor 1 antagonists PMX53 and PMX205 ( D ).

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Tandem Mass Spectroscopy, Targeted Proteomics, Mass Spectrometry, Liquid Chromatography

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: LC-MS/MS method’s accuracy and precision for PMX53 and PMX205 determination.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Clinical Proteomics

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: Process suitability and matrix influence for PMX53 and PMX205 determination.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Clinical Proteomics, Extraction

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: Stability studies for PMX53 and PMX205.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Clinical Proteomics

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: PMX53 and PMX205 stability studies: Stability study of PMX53 and PMX205 in serum, plasma, gastric and intestinal environment at 37 °C for 60 min ( A – F ). Line graph represents unchanged PMX53 and PMX205 at regular time intervals as determined by validated LC-MS/MS method. Data expressed as mean ± SEM of n = 4 of percentage of detected concentration compared to initial concentration values.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Clinical Proteomics, Liquid Chromatography with Mass Spectroscopy, Concentration Assay

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: Intravenous ( i . v .) pharmacokinetics of PMX53 and PMX205 in wild-type mice: Complement C5a receptor 1 antagonists PMX53 (red graph lines) and PMX205 (blue graph lines) concentration vs time profile in plasma ( A ), brain ( B ) and spinal cord ( C ) following single i . v . bolus drug dose of 1 mg/kg of either antagonist in mice at time = 0. Data points represent mean ± SEM of n = 4 mice at each time point.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Drug discovery, Concentration Assay, Clinical Proteomics

Journal: Scientific Reports

Article Title: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

doi: 10.1038/s41598-018-26387-4

Figure Lengend Snippet: PMX53 and PMX205 pharmacokinetic parameters.

Article Snippet: Complement C5aR1 antagonists, PMX53 (Ac-Phe-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) and PMX205 (hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]); (Fig. ) were kindly provided by Promics Pty Ltd, Australia, and were synthesized and characterised as previously described .

Techniques: Clinical Proteomics